Kornelia D. Galior
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kornelia D. Galior has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Alexandar Tzankov
Institute of Medical Genetics and Pathology, University Hospital Basel and University of Basel, Basel, Switzerland
1 shared publication Alicia Algeciras-Schimnich
Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
1 shared publicationAndrew K Godwin
Department of Pathology and Laboratory Medicine University of Kansas Medical Center Kansas City KS USA
1 shared publication- Antonio Lopez-Beltran
Department of Pathology, Cordoba University Medical School, Cordoba, Spain
1 shared publication António M Palma
Champalimaud Centre for the Unknown Lisbon Portugal
1 shared publication- Arutha Kulasinghe
The University of Queensland
1 shared publication
Latest Publications
- 20 December 2023
- Published by Elsevier
- Vol. 118, 205-223
Defining allowable total error limits in the clinical laboratory
- 20 December 2023
- Published by Elsevier
- Vol. 118, 205-223
Defining allowable total error limits in the clinical laboratory
- 15 November 2023
- Published by Elsevier in Clinical Biochemistry
- Vol. 121-122, 110685
Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays
- 15 November 2023
- Published by Elsevier in Clinical Biochemistry
- Vol. 121-122, 110685
Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays
- Open Access
- 18 October 2021
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 13 (11) , e13714
Flower lose, a cell fitness marker, predicts COVID‐19 prognosis
Risk stratification of COVID‐19 patients is essential for pandemic management. Changes in the cell fitness marker, hFwe‐Lose , can precede the host immune response to infection, potentially making such a biomarker an earlier triage tool. Here, we evaluate whether hFwe‐Lose gene expression can outperform conventional methods in predicting outcomes (e.g., death and hospitalization) in COVID‐19 patients. We performed a post‐mortem examination of infected lung tissue in deceased COVID‐19 patients to determine hFwe‐Lose’ s biological role in acute lung injury. We then performed an observational study ( n = 283) to evaluate whether hFwe‐Lose expression (in nasopharyngeal samples) could accurately predict hospitalization or death in COVID‐19 patients. In COVID‐19 patients with acute lung injury, hFwe‐Lose is highly expressed in the lower respiratory tract and is co‐localized to areas of cell death. In patients presenting in the early phase of COVID‐19 illness, hFwe‐Lose expression accurately predicts subsequent hospitalization or death with positive predictive values of 87.8–100% and a negative predictive value of 64.1–93.2%. hFwe‐Lose outperforms conventional inflammatory biomarkers and patient age and comorbidities, with an area under the receiver operating characteristic curve (AUROC) 0.93–0.97 in predicting hospitalization/death. Specifically, this is significantly higher than the prognostic value of combining biomarkers (serum ferritin, D‐dimer, C‐reactive protein, and neutrophil–lymphocyte ratio), patient age and comorbidities (AUROC of 0.67–0.92). The cell fitness marker, hFwe‐Lose , accurately predicts outcomes in COVID‐19 patients. This finding demonstrates how tissue fitness pathways dictate the response to infection and disease and their utility in managing the current COVID‐19 pandemic.
- 18 October 2021
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 13 (11) , e13714
Open AccessFlower lose, a cell fitness marker, predicts COVID‐19 prognosis
Risk stratification of COVID‐19 patients is essential for pandemic management. Changes in the cell fitness marker, hFwe‐Lose , can precede the host immune response to infection, potentially making such a biomarker an earlier triage tool. Here, we evaluate whether hFwe‐Lose gene expression can outperform conventional methods in predicting outcomes (e.g., death and hospitalization) in COVID‐19 patients. We performed a post‐mortem examination of infected lung tissue in deceased COVID‐19 patients to determine hFwe‐Lose’ s biological role in acute lung injury. We then performed an observational study ( n = 283) to evaluate whether hFwe‐Lose expression (in nasopharyngeal samples) could accurately predict hospitalization or death in COVID‐19 patients. In COVID‐19 patients with acute lung injury, hFwe‐Lose is highly expressed in the lower respiratory tract and is co‐localized to areas of cell death. In patients presenting in the early phase of COVID‐19 illness, hFwe‐Lose expression accurately predicts subsequent hospitalization or death with positive predictive values of 87.8–100% and a negative predictive value of 64.1–93.2%. hFwe‐Lose outperforms conventional inflammatory biomarkers and patient age and comorbidities, with an area under the receiver operating characteristic curve (AUROC) 0.93–0.97 in predicting hospitalization/death. Specifically, this is significantly higher than the prognostic value of combining biomarkers (serum ferritin, D‐dimer, C‐reactive protein, and neutrophil–lymphocyte ratio), patient age and comorbidities (AUROC of 0.67–0.92). The cell fitness marker, hFwe‐Lose , accurately predicts outcomes in COVID‐19 patients. This finding demonstrates how tissue fitness pathways dictate the response to infection and disease and their utility in managing the current COVID‐19 pandemic.